Last week, the U.S. Food and Drug Administration (FDA) announced that it would not allow…
View More FDA allows wide use of plasma for COVID-19 with little data that it works
FDA approves first contact lens that slows myopia progression
(HealthDay)—MiSight, the first contact lens indicated to slow the progression of myopia in children ages…
View More FDA approves first contact lens that slows myopia progression
FDA: blood clot, death risk up with higher dose of tofacitinib
New warnings about an increased risk of thrombosis and of death among ulcerative colitis patients…
View More FDA: blood clot, death risk up with higher dose of tofacitinib
The FDA Finally Issued A Recall For Breast Implants That Have Been Linked to Cancer
Breast implant manufacturer Allergan, Inc. issued a worldwide recall Wednesday of certain textured breast implant models—a…
View More The FDA Finally Issued A Recall For Breast Implants That Have Been Linked to Cancer
FDA Approves Supplemental New Drug Application to Expand Cinvanti (aprepitant) Label for IV Push
SAN DIEGO, Feb. 26, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology…
View More FDA Approves Supplemental New Drug Application to Expand Cinvanti (aprepitant) Label for IV Push
Sunscreen Chemicals Can Seep Into Your Bloodstream, FDA Says
It’s that time of year when doctors remind everyone to layer on the sunscreen. But…
View More Sunscreen Chemicals Can Seep Into Your Bloodstream, FDA Says
FDA approves mavyret for children, adolescents with hep C
(HealthDay)—Mavyret (glecaprevir and pibrentasvir) tablets are now approved to treat all six genotypes of hepatitis…
View More FDA approves mavyret for children, adolescents with hep C
FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
April 4, 2019 — Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration…
View More FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
Imbrium Therapeutics Announces FDA Orphan Drug Designation for Tinostamustine for The Treatment of T-Cell Prolymphocytic Leukemia
STAMFORD, Conn. – March 28, 2019 – Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and…
View More Imbrium Therapeutics Announces FDA Orphan Drug Designation for Tinostamustine for The Treatment of T-Cell Prolymphocytic Leukemia
More Women Reported to Have Rare Cancer Linked to Breast Implants
More cases of a rare cancer linked to breast implants have been reported in the…
View More More Women Reported to Have Rare Cancer Linked to Breast Implants